var data={"title":"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">John R Ingram, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Mark V Dahl, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 08, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hidradenitis suppurativa (HS, from the Greek hidros = sweat and aden = glands) is a chronic inflammatory skin condition that is also known as acne inversa and, historically, as Verneuil's disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Although the name &quot;hidradenitis suppurativa&quot; implies a suppurative disorder that primarily involves sweat glands, increasing knowledge of the pathogenesis of the condition has led to the prevailing theory that HS is a chronic follicular occlusive disease involving the follicular portion of folliculopilosebaceous units (FPSUs). </p><p>The primary sites of involvement for HS are the intertriginous skin areas of the axillary, groin, perianal, perineal, and inframammary regions, though HS can occur in any skin area that contains FPSUs. The clinical manifestations vary, ranging from recurrent inflamed nodules and abscesses to draining sinus tracts and bands of severe scar formation. The associated pain, malodor, drainage, and disfigurement that accompany HS contribute to a profound psychosocial impact of the disease on many patients [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Early HS lesions often mimic other disorders; misdiagnosis of HS as recurrent furunculosis or &quot;boils&quot; is common. Prompt recognition of the correct diagnosis is important. An early and accurate diagnosis facilitates the initiation of a treatment plan aimed at minimizing the risk of progression to disabling, end-stage disease. </p><p>The pathogenesis, clinical manifestations, and diagnosis of HS will be discussed here. Treatment is reviewed separately. (See <a href=\"topic.htm?path=hidradenitis-suppurativa-treatment\" class=\"medical medical_review\">&quot;Hidradenitis suppurativa: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Estimates of the prevalence of HS have varied, ranging from less than 1 percent to 4 percent [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4-8\" class=\"abstract_t\">4-8</a>]. The first population-based incidence study of HS found an annual age- and sex-adjusted incidence of 6 per 100,000 in a county in Minnesota [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. A subsequent, larger, population-based study that utilized data from a database of more than 48 million patients in the United States found a higher incidence (11.4 per 100,000 population) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>].</p><p>The onset of symptoms typically occurs between puberty and age 40, with usual onset in the second or third decade of life. Women are more likely to develop HS than men [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. In a French series of 618 consecutive patients with HS, the sex ratio was 3.6:1 [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. In addition, the large population-based study in the United States found that the incidence of HS was twice as high among women than among men; the highest age-specific incidence was among patients between the ages of 18 and 29 years [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of HS is not fully understood; however, new evidence is emerging [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. As opposed to early theories that implicated apocrine glands as the primary contributors to HS, most authors now support follicle-centered theories for the pathogenesis of HS. Follicular occlusion, follicular rupture, and an associated immune response appear to be important events in the development of the clinical manifestations of HS. The basic principles that underlie follicle-centered theories are reviewed below. </p><p class=\"headingAnchor\" id=\"H259634200\"><span class=\"h2\">Mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Follicular occlusion is the most likely event responsible for the initial development of HS lesions. Follicular occlusion appears to result from ductal keratinocyte proliferation (follicular epithelial hyperplasia), causing follicular hyperkeratosis and plugging [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. Proposed contributors have included the effects of hormones and nicotine on the follicular epithelium [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13-15\" class=\"abstract_t\">13-15</a>] (see <a href=\"#H259634222\" class=\"local\">'Associated factors'</a> below). It may be that that anoxia within the follicular duct secondary to follicular epithelial hyperplasia contributes to the disruption of normal terminal differentiation of follicular keratinocytes, leading to follicular plugging [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/16\" class=\"abstract_t\">16</a>].</p><p>As a consequence of the failure of terminal differentiation, the keratinocytes do not separate and the follicular duct expands. Mechanical stress (pressure, friction, or shear) on skin, particularly in intertriginous areas, results in leakage of molecular-sized antigens that stimulate the adaptive immune system as well as stimuli for the innate immune system. Subsequent cytokine release leads to activation of keratinocytes that release their own proinflammatory mediators [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>]. Perifolliculitis is detected at this stage [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13,18\" class=\"abstract_t\">13,18</a>]. If sufficient repair of the compromised follicular duct does not occur, the follicular duct eventually may rupture, leading to the release of macro follicular contents (eg, keratin fragments derived from corneocytes and hair, sebum products, bacteria), and the further recruitment of inflammatory cells [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>]. Over time, the initial acute inflammatory response may evolve into chronic foreign body-type granulomatous inflammation. </p><p>Defects in the support of the follicular wall may predispose individuals with HS to follicular rupture. A study that compared skin specimens from patients with HS to specimens from normal controls found that axillary specimens from patients with HS demonstrated a marked reduction in periodic acid-Schiff (PAS) staining of the basement membrane zone at the junction between the sebaceous gland and the follicle (sebofollicular junction) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. In contrast, continuous PAS staining was noted along the basement membrane zone of the folliculopilosebaceous unit in specimens from patients in the control group. </p><p>Follicular rupture may promote the formation of sinus tracts through the release of stem cells from the bulge area of the hair follicle that subsequently proliferate and form epithelial strands [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/17,19,20\" class=\"abstract_t\">17,19,20</a>]. Formed sinus tracts eventually open onto the skin surface and become chronically inflamed.</p><p>Questions remain about the role of the immune system in HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>], particularly whether dysregulation of the immune system is a contributor. Although activation of the innate and adaptive immune systems is an expected response to the release of antigens and other proinflammatory stimuli from a ruptured follicular duct, a role for immune system dysregulation in HS is suggested by similarities between HS and Crohn disease, an inflammatory bowel disorder hypothesized to involve dysregulation of the innate and adaptive immune systems. HS and Crohn disease share histologic features, and there is a well-established epidemiologic association between the two conditions [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Moreover, the inflammatory processes of both diseases may respond to anti-tumor necrosis factor (TNF)-alpha therapies [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/12,17,24-26\" class=\"abstract_t\">12,17,24-26</a>]. </p><p>Further studies are necessary to explore whether immune dysregulation is a primary contributor to the initiation of HS. Interleukin (IL)-17 and the caspase-1-associated cytokines IL-1beta and IL-18 may be involved in the disease pathogenesis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/27\" class=\"abstract_t\">27</a>]. Increased understanding of the role of the immune system may aid in the discovery of new treatments.</p><p class=\"headingAnchor\" id=\"H259634222\"><span class=\"h2\">Associated factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic susceptibility, mechanical stresses on the skin, obesity, smoking, diet, and hormonal factors are repeatedly cited as factors that may be associated with the development or exacerbation of HS. The relationships between these factors and HS are discussed below: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Genetics </strong>&ndash; Genetic susceptibility appears to be an important contributor to HS. It is estimated that approximately 40 percent of patients with HS have an affected first-degree family member [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>]. Compared with other HS patients, patients with early-onset HS (onset prior to age 13) may be more likely to have a family history of the disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>]</p><p/><p class=\"bulletIndent1\">Familial occurrences of HS resembling an autosomal dominant-like inheritance pattern have been documented (MIM #142690). A candidate locus for HS at chromosome 1p21.1-1q25.3 was identified via a genome-wide scan in a Chinese family that demonstrated an autosomal dominant pattern of inheritance and a particularly widespread form of HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>]. However, this locus was not associated with HS in two additional families with a more classic presentation in which an autosomal dominant inheritance pattern appeared to be present [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/31\" class=\"abstract_t\">31</a>]. </p><p/><p class=\"bulletIndent1\">Further studies are necessary to clarify the impact of genetics on risk for HS. The finding of mutations in genes encoding the components of gamma-secretase, an intramembranous protease complex that cleaves multiple transmembrane proteins, in kindreds with HS may contribute to further understanding of the disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/32-35\" class=\"abstract_t\">32-35</a>]. Gamma-secretase cleaves the intracellular domain of Notch, a transmembrane receptor protein that plays an important role in keratinocyte differentiation. Although it appears that germline gamma-secretase mutations may contribute to HS in only a small subset of patients [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>], familial and mouse studies support the theory that inherited or acquired impairment of Notch signalling may play a key role in disease development [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/36\" class=\"abstract_t\">36</a>]. The gamma-secretase mutations that have been reported in patients with HS include mutations in genes for presenilin-1 (PSEN1), presenilin enhancer-2 (PSENEN), and nicastrin (NCSTN) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/33,37-40\" class=\"abstract_t\">33,37-40</a>]. TNF gene polymorphisms also may play a role in susceptibility to HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanical stress </strong>&ndash; Increased mechanical stress (pressure, friction, shear) on intertriginous skin and other areas (eg, beltlines, brassiere straps, and other sites of clothing friction) likely contributes to the localization of HS. Mechanical stress on skin has been postulated to contribute to HS via increasing the chance of follicular occlusion and follicular rupture [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4,17\" class=\"abstract_t\">4,17</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Obesity </strong>&ndash; Excess weight is more common in patients with HS than in the general population; however, the disease is not limited to overweight or obese individuals. In a case-control study of 302 patients with HS and 906 controls, a body mass index (BMI) &ge;30 was present in 21 percent of patients with HS versus only 9 percent of controls and a BMI between 25 and 29 was present in 22 percent of HS patients versus 17 percent of controls [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/42\" class=\"abstract_t\">42</a>]. One theory for the association between excess weight and HS is that dietary choices that increase risk for the disease are those that also contribute to obesity [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>] (see &quot;Hormones&quot; below). Several studies have found a positive correlation between increasing BMI and disease severity [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/44-49\" class=\"abstract_t\">44-49</a>].</p><p/><p class=\"bulletIndent1\">As in acne vulgaris, hormonal changes associated with obesity may result in relative androgen excess and are proposed to increase follicular plugging [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/50\" class=\"abstract_t\">50</a>]. Moreover, the comparatively larger size of intertriginous areas, local skin irritation from sweat retention, narrowed follicular orifices secondary to intrafollicular keratin hydration during skin occlusion, and obesity-related increases in levels of circulating proinflammatory cytokines may contribute [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4,17,51\" class=\"abstract_t\">4,17,51</a>]; however, these factors are also present in obese individuals without HS. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Smoking </strong>&ndash;<strong> </strong>There is a strong relationship between smoking and HS; the majority of affected patients are smokers [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9,42,44,49,52\" class=\"abstract_t\">9,42,44,49,52</a>]. An American retrospective cohort study that included approximately four million tobacco smokers and approximately eight million nonsmokers found the overall incidence of HS higher among tobacco smokers (0.2 versus 0.1 percent) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/53\" class=\"abstract_t\">53</a>]. In a French case-control study of 302 clinically assessed patients with HS and 906 controls, 76 percent of the patients with HS versus 25 percent of the controls were current smokers [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/42\" class=\"abstract_t\">42</a>]. This particular study did not find an association between smoking and severity of disease; however, other studies have found more severe disease in smokers than nonsmokers [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9,44\" class=\"abstract_t\">9,44</a>]. In a study in which the modified Hidradenitis Suppurativa Score was used to assess disease severity in 115 patients with HS, the median score was significantly higher among the smokers than among the nonsmokers [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/44\" class=\"abstract_t\">44</a>]. Stimulatory effects of nicotine and other components of tobacco on follicular occlusion, neutrophil chemotaxis, TNF-alpha production by keratinocytes, and Th17 cells have been cited as potential contributing factors [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/12,54\" class=\"abstract_t\">12,54</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hormones </strong>&ndash;<strong> </strong>An impact of hormones on HS is suggested by observations of the rarity of HS in prepubertal children and improvement in HS during treatment with antiandrogenic agents [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/55-58\" class=\"abstract_t\">55-58</a>]. In addition, some women experience perimenstrual flares, and in this subgroup, amelioration of disease severity during pregnancy was found in a retrospective survey [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/59\" class=\"abstract_t\">59</a>]. Hyperandrogenemia seems unlikely to be a contributor to HS based upon a series of 66 women with HS that found no evidence of biochemical hyperandrogenism when compared with controls matched for age, weight, and hirsutism [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\">Additional studies are necessary to determine the role of hormones in HS.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bacteria </strong>&ndash; The role of bacteria in HS is controversial. Cultures from early, unruptured HS lesions are usually sterile. Older and ruptured lesions and sinuses may demonstrate a wide variety of bacteria (eg, staphylococci, streptococci, Gram-negative rods, and anaerobic bacteria). Coagulase-negative staphylococci are frequently present [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/61,62\" class=\"abstract_t\">61,62</a>]. Positive cultures may represent contaminants from normal skin flora or secondary infection. One theory suggests that bacteria may contribute to HS by promoting an inflammatory response [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>], and a role for a bacterial biofilm in the persistence of the inflammatory process of HS has been proposed [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. In addition, a case-control study found significant differences in the microbiome of lesional and nonlesional skin in 30 patients with HS compared with 24 healthy controls [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drugs </strong>&ndash; In support of a contribution of androgens to HS, there are reports of female patients in whom treatment with oral contraceptives containing androgenic progestins, intramuscular <a href=\"topic.htm?path=medroxyprogesterone-acetate-drug-information\" class=\"drug drug_general\">medroxyprogesterone acetate</a>, or <a href=\"topic.htm?path=levonorgestrel-systemic-drug-information\" class=\"drug drug_general\">levonorgestrel</a> in an intrauterine device may precipitate or worsen HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/66\" class=\"abstract_t\">66</a>]. <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a> therapy has been linked to HS in a small number of patients [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/67,68\" class=\"abstract_t\">67,68</a>]. Paradoxically, HS has been reported as an adverse effect of anti-TNF-alpha therapies and other biologic treatments given for other chronic inflammatory diseases [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/69\" class=\"abstract_t\">69</a>].</p><p/><p class=\"headingAnchor\" id=\"H259635175\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HS predominantly occurs in intertriginous areas. HS can affect the axillae (most common site), inguinal area, inner thighs, perianal and perineal areas, mammary and inframammary regions, buttocks, pubic region, scrotum, vulva, trunk, and, occasionally, the scalp and retroauricular areas (<a href=\"image.htm?imageKey=OBGYN%2F77990%7EOBGYN%2F65884%7EOBGYN%2F65188\" class=\"graphic graphic_picture graphicRef77990 graphicRef65884 graphicRef65188 \">picture 1A-C</a>) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/70\" class=\"abstract_t\">70</a>]. Early-onset HS may be associated with a greater risk for widespread disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Sex influences the distribution of HS. Primary sites of involvement in women are the groin or upper inner thigh, axilla, chest (including breast and inframammary regions), and the buttocks or gluteal clefts [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9,71\" class=\"abstract_t\">9,71</a>]. In men, primary sites of involvement are the groin or thigh, axilla, perineal or perianal regions, and buttocks or gluteal cleft [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9,47,71\" class=\"abstract_t\">9,47,71</a>]. Both sexes regularly show involvement in non-intertriginous skin, particularly at sites of skin compression and friction. Beltlines, waistbands, abdominal folds, and brassiere straps or bands are common locations. </p><p>Given the heterogeneity in clinical presentation within the HS phenotype, attempts have been made to generate disease subclassifications [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. However, these models have not been related to response to treatment. </p><p>The primary visible lesions of HS are inflammatory nodules. Sinus formation, clusters of open comedones (tombstone comedones), and scarring are the result of recurrent or persistent disease.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inflammatory nodules </strong>&ndash; Most frequently, the first lesion is a solitary, painful, deep-seated inflamed nodule (0.5 to 2 cm in diameter), often in an intertriginous area. Onset can be insidious, with occasional solitary, painful nodules that can last for several days to months. Recurrent episodes of nodule formation may occur in the exact same location or in the same skin region. </p><p/><p class=\"bulletIndent1\">The diagnosis of HS is frequently missed at this stage. In a survey including 517 patients in 24 countries, diagnostic delay on average was seven years [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>]. The inflammatory nodules are commonly misdiagnosed as &quot;boils&quot; or furunculosis. Unlike furuncles, primary HS lesions are deep-seated and round-topped, and lack the pointed appearance of furuncles [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>]. The nodules are painful, and depending on the location and size of lesions, patients may be unable to walk or sit without pain [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/73\" class=\"abstract_t\">73</a>]. </p><p/><p class=\"bulletIndent1\">After a variable period of time, the nodule often progresses to form an abscess that may open to the skin surface spontaneously (or as a result of manipulation by the patient), yielding purulent or serosanguineous drainage (<a href=\"image.htm?imageKey=DERM%2F69605\" class=\"graphic graphic_picture graphicRef69605 \">picture 2</a>). Pain often improves after drainage. Other nodules regress without draining, usually within one to several weeks [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>]. In a questionnaire-based study of 110 patients with HS, patients reported that the average duration of a single painful lesion was seven days, although approximately 60 percent of patients described at least one persistent painful nodule that failed to subside completely [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>]. The number and frequency of nodules varies widely among patients. Patients in this study reported a median of two nodules per month (range 1 per year to 30 per month). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sinus tracts </strong>&ndash; Sinus tracts are typical findings in HS that persist for months or years and contribute to symptomatology (<a href=\"image.htm?imageKey=DERM%2F52570\" class=\"graphic graphic_picture graphicRef52570 \">picture 3</a>). The development of multiple recurrent nodules within a limited area may predispose to the formation of intercommunicating sinuses. Patients with sinus tracts often experience intermittent release of blood-stained, seropurulent, malodorous discharge. Sinus tracts are not always palpable, and in some cases, a sinus tract becomes apparent only when a substance (eg, local anesthetic) injected into a lesion appears at a site distant from the site of injection. Ulceration may accompany sinus tract formation. Occasionally, pyogenic granulomas develop at sinus tract openings [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/74\" class=\"abstract_t\">74</a>]. (See <a href=\"topic.htm?path=pyogenic-granuloma-lobular-capillary-hemangioma\" class=\"medical medical_review\">&quot;Pyogenic granuloma (Lobular capillary hemangioma)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Comedones </strong>&ndash; Open comedones often appear in long-standing HS, commonly as double-headed or multi-headed open comedones [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/75\" class=\"abstract_t\">75</a>]. These structures are often described as &quot;tombstone comedones&quot; because they reflect end stage damage to the folliculopilosebaceous unit with associated loss of the sebaceous gland and hair [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/76\" class=\"abstract_t\">76</a>]. &#160;</p><p/><p class=\"bulletIndent1\">Closed comedones may also develop in HS. The closed comedones of HS are essentially tiny cysts that result from continued keratin production by the follicular epithelium lining the residual stub of the follicle above the destroyed sebofollicular junction. Closed comedones are not primary lesions and therefore, are not present in early cases of HS. The presence of comedones is not required for the diagnosis of early disease. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Scarring </strong>&ndash;<strong> </strong>The appearance of healed areas ranges from individual, pitted, acneiform scars after resolution of small nodules to dense, fibrotic bands or indurated, thick, scarred plaques affecting the whole affected area. Scars may also be atrophic (particularly on the trunk) or keloidal, and scarring on the buttocks sometimes manifests as multiple pitted scars. In patients with active disease, scarring is accompanied by inflammatory nodules and draining sinuses. </p><p/><p>In areas of lax flexural skin, such as the axilla, scarring can result in thick, linear, rope-like bands. Severe scarring in the axilla may result in reduced mobility of the arm or lymphatic obstruction leading to lymphedema. Groin involvement may lead to lymphedema of the pubis or the entire vulvar area in women or penile <span class=\"nowrap\">and/or</span> scrotal lymphedema in men [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/77\" class=\"abstract_t\">77</a>]. </p><p>HS has a significant impact on patient quality of life [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>]. Pain is a major cause of disutility, along with scarring, the unpredictable discharge, the necessary dressings, and the accompanying odor, which are embarrassing and humiliating [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/78\" class=\"abstract_t\">78</a>]. As a result, patients may experience social isolation, depression, failed relationships, and loss of (or failure to gain) employment [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/79,80\" class=\"abstract_t\">79,80</a>]. An increased suicide risk has also been reported among patients with HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/81\" class=\"abstract_t\">81</a>]. Prodromal symptoms may also be experienced prior to disease flares, including fatigue and localized pruritus or paresthesias [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/82\" class=\"abstract_t\">82</a>].</p><p class=\"headingAnchor\" id=\"H605085050\"><span class=\"h1\">CLINICAL STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Hurley clinical staging system frequently is used to divide patients with HS into three disease severity groups [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage I </strong>&ndash; Abscess formation (single or multiple) without sinus tracts and <span class=\"nowrap\">cicatrization/scarring</span> (<a href=\"image.htm?imageKey=DERM%2F90463\" class=\"graphic graphic_picture graphicRef90463 \">picture 4</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage II </strong>&ndash; Recurrent abscesses with sinus tracts and scarring, single or multiple widely separated lesions (<a href=\"image.htm?imageKey=DERM%2F90464\" class=\"graphic graphic_picture graphicRef90464 \">picture 5</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage III </strong>&ndash; Diffuse or almost diffuse involvement, or multiple interconnected sinus tracts and abscesses across the entire area (<a href=\"image.htm?imageKey=DERM%2F90465\" class=\"graphic graphic_picture graphicRef90465 \">picture 6</a>)</p><p/><p>The majority of patients with HS exhibit stage I disease. In a French series of 302 consecutive patients with HS, stage I, II, and III disease were observed in 68, 28, and 4 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H106560796\"><span class=\"h1\">ASSOCIATED DISORDERS AND SYNDROMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of disorders have been linked to HS. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emerging data indicate that patients with HS may have increased incidence of (and risk for) metabolic syndrome and related comorbidities, a constellation of metabolic and secondary disorders including diabetes, obesity, insulin resistance, dyslipidemia, hyperglycemia, and hypertension [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/48,84-89\" class=\"abstract_t\">48,84-89</a>]. In combination with higher rates of smoking in HS, these factors contribute to a higher risk of cardiovascular-associated death; the risk was nearly double that of a control group in Danish HS patients [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/90\" class=\"abstract_t\">90</a>]. In this climate, patients with HS should be offered the benefit of a multidisciplinary approach to aid in prevention, detection, and management of cardiovascular disease. (See <a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">&quot;The metabolic syndrome (insulin resistance syndrome or syndrome X)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several studies suggest an association between HS and inflammatory bowel disease (IBD) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/23,25,91-93\" class=\"abstract_t\">23,25,91-93</a>]. As an example, an Israeli cross-sectional study of 3207 patients with a diagnosis of HS and 6412 matched controls found an association with Crohn disease (odds ratio 2.03, 95% CI 1.14-3.62) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/91\" class=\"abstract_t\">91</a>]. In addition, a population-based cohort study of 679 patients with Crohn disease or ulcerative colitis in the United States found these patients more likely to develop HS than the general population (incidence rate ratio 8.9, 95% CI 3.6-17.5) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/92\" class=\"abstract_t\">92</a>]. Patients with IBD and HS tend to be younger than patients with IBD alone and are more likely to be smokers and have other comorbid conditions (eg, obesity, diabetes mellitus) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/94,95\" class=\"abstract_t\">94,95</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis and prognosis of Crohn disease in adults&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acne vulgaris is a common condition that may be seen in association with HS. Acne vulgaris can be particularly severe and difficult to treat in patients with HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HS is a component of the follicular occlusion tetrad. The follicular occlusion tetrad consists of four diagnoses: HS, acne conglobata, dissecting cellulitis of the scalp, and pilonidal sinus. These four conditions are considered to share follicular occlusion as a key pathogenic event and may appear in conjunction with one another in individual patients [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/93,96\" class=\"abstract_t\">93,96</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris#H14\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;, section on 'Acne conglobata'</a> and <a href=\"topic.htm?path=evaluation-and-diagnosis-of-hair-loss#H1871427\" class=\"medical medical_review\">&quot;Evaluation and diagnosis of hair loss&quot;, section on 'Cicatricial alopecia'</a> and <a href=\"topic.htm?path=pilonidal-disease\" class=\"medical medical_review\">&quot;Pilonidal disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are isolated reports of patients in whom HS has appeared to develop within a syndrome-like presentation consisting of several inflammatory diseases. <strong>PAPASH syndrome </strong>(pyogenic arthritis, pyoderma gangrenosum, acne, and suppurative hidradenitis) has been described in an adolescent in whom a mutation in the <em>PSTPIP1</em> gene was detected [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/97\" class=\"abstract_t\">97</a>]. The term <strong>PASH syndrome</strong> has been used to refer to patients with pyoderma gangrenosum, acne, and suppurative hidradenitis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/98-100\" class=\"abstract_t\">98-100</a>]. Genetic analysis has revealed a <em>PSTPIP1</em> mutation in a patient with PASH syndrome [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/101\" class=\"abstract_t\">101</a>]; however, in two other patients with PASH syndrome <em>PSTPIP1</em> mutations were absent [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/98\" class=\"abstract_t\">98</a>]. </p><p/><p>Other conditions, including inflammatory, neoplastic, and genetic disorders have been associated with HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/102\" class=\"abstract_t\">102</a>]. A table listing examples of associated disorders is provided (<a href=\"image.htm?imageKey=DERM%2F75490\" class=\"graphic graphic_table graphicRef75490 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H605084968\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic findings in HS vary according to the stage of the lesion (<a href=\"image.htm?imageKey=DERM%2F90466\" class=\"graphic graphic_picture graphicRef90466 \">picture 7</a>). Common early features include follicular hyperkeratosis, follicular plugging, follicular dilation, and lymphocytic perifolliculitis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. Biopsies of established areas of disease can demonstrate additional features, including psoriasiform hyperplasia of the interfollicular epithelium [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>] or a dense, mixed inflammatory infiltrate involving the lower half of the dermis and subcutis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/103\" class=\"abstract_t\">103</a>]. In addition, chronic abscesses, sinus tracts lined by stratified squamous epithelium, and granulation tissue with or without foreign body giant cells may be present. Destruction of folliculopilosebaceous units, fibrosis, and incidental peri-apocrine and peri-eccrine inflammation also may be evident [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/51,74\" class=\"abstract_t\">51,74</a>]. </p><p class=\"headingAnchor\" id=\"H605085009\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of HS is made from the patient history and recognition of characteristic clinical manifestations [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H366566\"><span class=\"h2\">History and physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The three main clinical features that support a diagnosis of HS are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Typical lesions </strong>(multiple deep-seated inflamed nodules, tombstone comedones, sinus tracts, abscesses <span class=\"nowrap\">and/or</span> fibrotic scars)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Typical locations </strong>(in particular,<strong> </strong>axillae, groin, inframammary areas; often bilateral distribution)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Relapses and chronicity</strong></p><p/><p>A diagnosis of HS is straightforward in patients who demonstrate the constellation of recurrent inflammatory nodules, sinus tracts, and hypertrophic scarring in intertriginous areas. However, the location, type, number, and severity of typical lesions vary widely among patients with HS. Thus, clinicians should maintain high suspicion for the diagnosis for all patients who present with recurrent inflammatory nodules, particularly when intertriginous involvement is present. Recognition of this feature and the characteristic patterns of scarring may allow for recognition of the disease at early stages.</p><p>The patient history can be a valuable tool in the diagnosis of HS. Onset in adolescence or young adulthood, a history of recurrent or persistent disease, or a family history of HS offer support for a diagnosis. Patients with atypical features also should be questioned about gastrointestinal symptoms to identify patients who may benefit from an evaluation for Crohn disease. (See <a href=\"#H605085221\" class=\"local\">'Differential diagnosis'</a> below and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis and prognosis of Crohn disease in adults&quot;</a>.)</p><p>A full skin examination should be performed in patients with suspected HS. This allows for an assessment of the extent and severity of involvement and the recognition of features that are more or less consistent with this disease.</p><p class=\"headingAnchor\" id=\"H366572\"><span class=\"h2\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy usually is not necessary for diagnosis. However, in cases in which the diagnosis is uncertain, a biopsy can be useful for excluding other disorders. A biopsy should also be performed if features suggestive of squamous cell carcinoma (SCC) are present. SCC may appear as a slowly growing, firm, nonfluctuant and nondraining mass that is superficially eroded or ulcerated and is located in an area of chronic HS. </p><p>Routine bacterial cultures are not indicated [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>]. Cultures are reserved for cases in which the clinical findings are suggestive of a primary infectious disorder rather than HS or if there is clinical evidence of secondary cellulitis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>]. No serologic studies confirm a diagnosis of HS. </p><p class=\"headingAnchor\" id=\"H366578\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiologic imaging is not necessary for the diagnosis of HS. However, ultrasound may be useful for preoperative assessment of the subclinical extent of disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5,104-106\" class=\"abstract_t\">5,104-106</a>]. Magnetic resonance imaging may be helpful for delineating extensive anogenital disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/107\" class=\"abstract_t\">107</a>].</p><p class=\"headingAnchor\" id=\"H605085221\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A few diseases produce inflamed nodules, recurrent abscesses, or sinus tracts that may be mistaken for HS. The patient history and clinical findings are usually sufficient for distinguishing HS from other diseases. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Follicular pyodermas (folliculitis, furuncles, carbuncles) </strong>&ndash; Folliculitis, furuncles (&quot;boils&quot;), and carbuncles are infections arising from hair follicles. Infectious folliculitis usually presents with multiple, superficial, inflammatory papules, each surrounding a hair follicle, with or without an overlying pustule. Infection that progresses to a nodular abscess is termed a furuncle. Carbuncles occur when several inflamed follicles converge into a single inflammatory mass with purulent drainage emanating from multiple areas. Unlike HS, which typically exhibits a chronic and recurrent course, follicular pyodermas are transient lesions that usually respond rapidly to appropriate antibiotic therapy. In addition, the follicular pyodermas do not cause the comedones, persistent sinus tracts, and hypertrophic scarring observed in HS. (See <a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cellulitis and skin abscess: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Acne vulgaris </strong>&ndash; Like HS, acne vulgaris demonstrates follicular hyperkeratinization leading to comedones, inflammatory nodules, and scarring. Although there is some overlap in the distribution of the two diseases, acne vulgaris primarily occurs on the face, upper chest, and back, whereas HS primarily involves the axillae, groin, buttocks, and inframammary folds. In addition, HS typically causes more deep-seated lesions, and several of its consequences, including sinus tracts and &quot;rope-like&quot; scars, provide characteristic clinical features. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intergluteal pilonidal disease </strong>&ndash; Intergluteal pilonidal disease manifests as a cavity, pit, or sinus in the area of the natal cleft that may become inflamed, swollen, and painful with associated mucoid, purulent, or bloody drainage. Along with hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp, pilonidal disease is a member of the follicular occlusion tetrad. Thus, pilonidal disease and HS may occur in the same patient, and there is ongoing debate regarding whether pilonidal disease is a phenotypic variant of HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/108\" class=\"abstract_t\">108</a>]. (See <a href=\"topic.htm?path=pilonidal-disease\" class=\"medical medical_review\">&quot;Pilonidal disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Crohn disease</strong> &ndash; Perianal and vulvar manifestations of Crohn disease include abscesses, rectoperineal and rectovaginal fistulae, sinus tracts, fenestrations, and scarring, as well as classic &quot;knife-cut&quot; ulcers in the inguinal, genitocrural, or interlabial folds (<a href=\"image.htm?imageKey=OBGYN%2F81233%7EOBGYN%2F58354\" class=\"graphic graphic_picture graphicRef81233 graphicRef58354 \">picture 8A-B</a>). A history of gastrointestinal Crohn disease supports this diagnosis; however, the simultaneous development of Crohn disease and HS has been reported [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/24,25\" class=\"abstract_t\">24,25</a>]. (See <a href=\"topic.htm?path=perianal-complications-of-crohn-disease\" class=\"medical medical_review\">&quot;Perianal complications of Crohn disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granuloma inguinale </strong>&ndash; Granuloma inguinale (donovanosis) is a sexually transmitted infection caused by <em>Klebsiella granulomatis</em> that usually occurs on the vulva, penis, scrotum, glans, inguinal folds, or perianal skin (<a href=\"image.htm?imageKey=OBGYN%2F71166\" class=\"graphic graphic_picture graphicRef71166 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/109\" class=\"abstract_t\">109</a>]. Lesions usually present as succulent red ulcers with granulation tissue that bleeds easily and with a foul odor. The presence of an enlarging ulcer with an undermined border suggests this diagnosis over HS. The causative organism cannot be cultured. Diagnosis requires visualization of Donovan bodies on tissue crush preparation or biopsy.</p><p/><p>Examples of other disorders that may enter the differential diagnosis of HS include actinomycosis, anal fistula, cat-scratch disease, cellulitis, inflamed epidermoid cyst, ischiorectal abscess, lymphogranuloma venereum, nocardiosis, noduloulcerative syphilis, perirectal abscess, tuberculous abscess, and tularemia [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. </p><p class=\"headingAnchor\" id=\"H605085626\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long-standing, poorly controlled HS may lead to significant physical and emotional consequences. Complications include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strictures and contractures [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphatic obstruction, lymphedema of limbs and genitalia</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malaise, depression, and suicide</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long-term effects of chronic inflammation including anemia, hypoproteinemia, and amyloidosis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infectious complications (eg, lumbosacral epidural abscess, sacral bacterial osteomyelitis) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>] </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arthritis [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/110\" class=\"abstract_t\">110</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Squamous cell carcinoma (SCC)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anemia [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/111\" class=\"abstract_t\">111</a>]</p><p/><p>Fistulae into the urethra, bladder, rectum, and peritoneum are a reported complication of HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/70\" class=\"abstract_t\">70</a>]. However, confusion with Crohn disease or coexistence of HS with Crohn disease may be responsible for these reports. </p><p>SCC arising in HS is rare but has been reported in at least 64 cases and appears to be more common in men [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/112-118\" class=\"abstract_t\">112-118</a>]. A 2011 review of published cases of cutaneous SCC arising in HS found that SCC primarily occurred 20 to 30 years after the onset of HS (range 2 to 50 years) [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/117\" class=\"abstract_t\">117</a>]. Approximately half of these patients died of metastatic disease [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/117\" class=\"abstract_t\">117</a>]. Human papilloma virus infection may be an important contributing factor to the development of SCC in lesions of HS [<a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/116\" class=\"abstract_t\">116</a>]. </p><p class=\"headingAnchor\" id=\"H3595492839\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hidradenitis-suppurativa\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hidradenitis suppurativa&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H366717\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hidradenitis suppurativa (HS) refers to a painful, chronic, suppurative process involving the skin and subcutaneous tissue. The clinical manifestations of HS appear to result from infra-infundibular follicular occlusion and secondary rupture of the sebofollicular junction of folliculopilosebaceous units (FPSUs), resulting in an inflammatory cascade. HS is neither contagious nor due to poor hygiene. (See <a href=\"#H5\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HS primarily occurs on intertriginous skin. The axilla is the most common site; the inguinal area, inner thighs, perineal and perianal areas, mammary and inframammary skin, and buttocks are additional common sites for involvement. Nonintertriginous skin involvement also can occur. (See <a href=\"#H259635175\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial presentation of HS typically involves recurrent, painful, and inflamed nodules. The nodules may rupture, discharging purulent, sometimes malodorous material. Persistent disease leads to coalescence of nodules into inflammatory plaques, epithelialized sinuses, end-stage &quot;tombstone&quot; comedones, and characteristic &quot;rope-like&quot; scarring. (See <a href=\"#H259635175\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis of HS is based upon the recognition of characteristic clinical manifestations, including typical lesions in intertriginous sites occurring on a chronic, recurrent basis. A skin biopsy usually is not necessary for diagnosis. Routine performance of bacterial cultures is not indicated. (See <a href=\"#H605085009\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of early stage HS is often missed. The clinician should have a high index of suspicion for the disease in individuals misdiagnosed with recurrent furuncles or &quot;boils&quot; in intertriginous areas after puberty. (See <a href=\"#H605085009\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H675002085\"><span class=\"h1\">ACKNOWLEDGMENTS</span></p><p>The editorial staff at UpToDate would like to acknowledge Lynette Margesson, MD, FRCPC, FAAD, who contributed to an earlier version of this topic review.</p><p>We are saddened by the death of F. William Danby, MD, FRCPC, FAAD, who passed away in November 2016. UpToDate wishes to acknowledge Dr. Danby's past work as an author for this topic.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Sellheyer K, Krahl D. &quot;Hidradenitis suppurativa&quot; is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44:535.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Bazex J, Bayle P, San B. Hidradenitis suppurativa is acne inversa. Int J Dermatol 2007; 46:330; author reply 330.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Kouris A, Platsidaki E, Christodoulou C, et al. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology 2016; 232:687.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60:539.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366:158.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68:412.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">McMillan K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. Am J Epidemiol 2014; 179:1477.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Garg A, Kirby JS, Lavian J, et al. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol 2017; 153:760.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133:97.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol 2017; 77:118.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 2013; 133:1506.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 21:735.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164:367.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Hana A, Booken D, Henrich C, et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80:2214.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Melnik BC, Plewig G. Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol 2013; 168:876.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18:821.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011; 672:1.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19:533.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Danby FW, Jemec GB, Marsch WCh, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013; 168:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Gniadecki R, Jemec GB. Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp Dermatol 2004; 13:361.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17:455.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Egeberg A, Jemec GBE, Kimball AB, et al. Prevalence and Risk of Inflammatory Bowel&nbsp;Disease in Patients with Hidradenitis&nbsp;Suppurativa. J Invest Dermatol 2017; 137:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Deckers IE, Benhadou F, Koldijk MJ, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study. J Am Acad Dermatol 2017; 76:49.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 38:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162:195.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156:51.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173:1431.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14:389.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol 2015; 72:485.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Gao M, Wang PG, Cui Y, et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126:1302.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Al-Ali FM, Ratnamala U, Mehta TY, et al. Hidradenitis suppurativa (or Acne inversa) with autosomal dominant inheritance is not linked to chromosome 1p21.1-1q25.3 region. Exp Dermatol 2010; 19:851.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Pink AE, Simpson MA, Desai N, et al. Mutations in the &gamma;-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol 2012; 132:2459.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Pink AE, Simpson MA, Desai N, et al. &gamma;-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 2013; 133:601.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Ingram JR. The Genetics of Hidradenitis Suppurativa. Dermatol Clin 2016; 34:23.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Frew JW, Vekic DA, Woods J, Cains GD. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol 2017; 177:987.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol 2013; 22:172.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Li CR, Jiang MJ, Shen DB, et al. Two novel mutations of the nicastrin gene in Chinese patients with acne inversa. Br J Dermatol 2011; 165:415.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Jiao T, Dong H, Jin L, et al. A novel nicastrin mutation in a large Chinese family with hidradenitis suppurativa. Br J Dermatol 2013; 168:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Chen S, Mattei P, You J, et al. &gamma;-Secretase Mutation in an African American Family With Hidradenitis Suppurativa. JAMA Dermatol 2015; 151:668.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Xu H, Xiao X, Hui Y, et al. Phenotype of 53 Chinese individuals with nicastrin gene mutations in association with familial hidradenitis suppurativa (acne inversa). Br J Dermatol 2016; 174:927.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Savva A, Kanni T, Damoraki G, et al. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 2013; 168:311.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59:596.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Danby FW. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol 2015; 73:S52.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61:51.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Crowley JJ, Mekkes JR, Zouboulis CC, et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014; 171:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Schrader AM, Deckers IE, van der Zee HH, et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014; 71:460.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 2015; 173:464.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Bettoli V, Naldi L, Cazzaniga S, et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 2016; 174:195.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol 2013; 22:311.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133:254.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">K&ouml;nig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198:261.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol 2018; 178:709.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Mortaz E, Adcock IM, Ito K, et al. Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J 2010; 36:1143.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 2005; 16:75.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol 2013; 149:732.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11:125.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115:263.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Vossen AR, van Straalen KR, Prens EP, van der Zee HH. Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. J Am Acad Dermatol 2017; 76:155.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996; 134:1057.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140:90.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Sartorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol 2012; 166:879.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Kathju S, Lasko LA, Stoodley P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol 2012; 65:385.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 2017; 176:993.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Ring HC, Thorsen J, Saunte DM, et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol 2017; 153:897.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ 1989; 298:28.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995; 32:382.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Aithal V, Appaih P. Lithium induced hidradenitis suppurativa and acne conglobata. Indian J Dermatol Venereol Leprol 2004; 70:307.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016; 74:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56:451.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23:985.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173:1546.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain 2010; 26:435.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34:994.</a></li><li class=\"breakAll\">Poli F, Jemec GBE, Revuz J. Clinical presentation. In: Hidradenitis suppurativa, Jemecs GBE, Revuz J, Leyden JJ (Eds), Heidelberg, Germany 2006. p.12-15.</li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">Kamp S, Fiehn AM, Stenderup K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Baughman SM, Cespedes RD. Unusual presentation of hidradenitis suppurativa with massive enlargement of penis. Urology 2004; 64:377.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D. Acta Derm Venereol 2016; 96:222.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27:473.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Deckers IE, Kimball AB. The Handicap of Hidradenitis Suppurativa. Dermatol Clin 2016; 34:17.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Thorlacius L, Cohen AD, Gislason GH, et al. Increased Suicide Risk in Patients with Hidradenitis Suppurativa. J Invest Dermatol 2018; 138:52.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Ring HC, Theut Riis P, Zarchi K, et al. Prodromal symptoms in hidradenitis suppurativa. Clin Exp Dermatol 2017; 42:261.</a></li><li class=\"breakAll\">Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic surgery, Roenigk RK, Roenigk HH (Eds), New York 1989. p.729.</li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150:1273.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014; 70:699.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 2015; 173:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Gonz&aacute;lez-L&oacute;pez MA, Hern&aacute;ndez JL, Lacalle M, et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol 2016; 75:329.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Garg A, Birabaharan M, Strunk A. Prevalence of Type II Diabetes Mellitus Among Patients with Hidradenitis Suppurativa in the United States. J Am Acad Dermatol 2018.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2016; 152:429.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Shalom G, Freud T, Ben Yakov G, et al. Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Cross-Sectional Study of&nbsp;3,207 Patients. J Invest Dermatol 2016; 136:1716.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis Suppurativa in Patients With Inflammatory Bowel&nbsp;Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2016; 14:65.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/93\" class=\"nounderline abstract_t\">Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J 2003; 9:8.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Lukach AJ, Saul MI, Ferris LK, Swoger JM. Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018; 63:755.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Ramos-Rodriguez AJ, Timerman D, Khan A, et al. The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. Int J Dermatol 2018.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/96\" class=\"nounderline abstract_t\">Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg 1987; 18:230.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/97\" class=\"nounderline abstract_t\">Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149:762.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/98\" class=\"nounderline abstract_t\">Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66:409.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/99\" class=\"nounderline abstract_t\">Marzano AV, Ishak RS, Colombo A, et al. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology 2012; 225:215.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/100\" class=\"nounderline abstract_t\">Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 2014; 93:e187.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/101\" class=\"nounderline abstract_t\">Calder&oacute;n-Castrat X, Bancalari-D&iacute;az D, Rom&aacute;n-Curto C, et al. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol 2016; 175:194.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/102\" class=\"nounderline abstract_t\">Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2:9.</a></li><li class=\"breakAll\">Weedon D. Diseases of cutaneous appendages. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, Edinburgh 2010. p.397.</li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/104\" class=\"nounderline abstract_t\">Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007; 33:1340.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/105\" class=\"nounderline abstract_t\">Wortsman X, Castro A, Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol 2016; 75:760.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/106\" class=\"nounderline abstract_t\">Wortsman X, Rodriguez C, Lobos C, et al. Ultrasound Diagnosis and Staging in Pediatric Hidradenitis Suppurativa. Pediatr Dermatol 2016; 33:e260.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/107\" class=\"nounderline abstract_t\">Griffin N, Williams AB, Anderson S, et al. Hidradenitis suppurativa: MRI features in anogenital disease. Dis Colon Rectum 2014; 57:762.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/108\" class=\"nounderline abstract_t\">von Laffert M, Stadie V, Ulrich J, et al. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. Dermatology 2011; 223:349.</a></li><li class=\"breakAll\">Kibbi, AG, El-Shareef, M. Granuloma inguinale. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff, K, Goldsmith, LA, Katz, SI, et al. (Eds), McGraw Hill, 2008. p.1990.</li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/110\" class=\"nounderline abstract_t\">Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 1994; 53:64.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/111\" class=\"nounderline abstract_t\">Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J 2013; 19:18558.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/112\" class=\"nounderline abstract_t\">DONSKY HJ, MENDELSON CG. SQUAMOUS CELL CARCINOMA AS A COMPLICATION OF HIDRADENITIS SUPPURATIVA. Arch Dermatol 1964; 90:488.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/113\" class=\"nounderline abstract_t\">Anstey AV, Wilkinson JD, Lord P. Squamous cell carcinoma complicating hidradenitis suppurativa. Br J Dermatol 1990; 123:527.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/114\" class=\"nounderline abstract_t\">Mendon&ccedil;a H, Rebelo C, Fernandes A, et al. Squamous cell carcinoma arising in hidradenitis suppurativa. J Dermatol Surg Oncol 1991; 17:830.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/115\" class=\"nounderline abstract_t\">Zachary LS, Robson MC, Rachmaninoff N. Squamous cell carcinoma occurring in hidradenitis suppurativa. Ann Plast Surg 1987; 18:71.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/116\" class=\"nounderline abstract_t\">Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220:147.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/117\" class=\"nounderline abstract_t\">Losanoff JE, Sochaki P, Khoury N, et al. Squamous cell carcinoma complicating chronic suppurative hydradenitis. Am Surg 2011; 77:1449.</a></li><li><a href=\"https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis/abstract/118\" class=\"nounderline abstract_t\">Maclean GM, Coleman DJ. Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 2007; 89:709.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5575 Version 33.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H366717\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">PATHOGENESIS</a><ul><li><a href=\"#H259634200\" id=\"outline-link-H259634200\">Mechanism</a></li><li><a href=\"#H259634222\" id=\"outline-link-H259634222\">Associated factors</a></li></ul></li><li><a href=\"#H259635175\" id=\"outline-link-H259635175\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H605085050\" id=\"outline-link-H605085050\">CLINICAL STAGING</a></li><li><a href=\"#H106560796\" id=\"outline-link-H106560796\">ASSOCIATED DISORDERS AND SYNDROMES</a></li><li><a href=\"#H605084968\" id=\"outline-link-H605084968\">HISTOPATHOLOGY</a></li><li><a href=\"#H605085009\" id=\"outline-link-H605085009\">DIAGNOSIS</a><ul><li><a href=\"#H366566\" id=\"outline-link-H366566\">History and physical examination</a></li><li><a href=\"#H366572\" id=\"outline-link-H366572\">Laboratory studies</a></li><li><a href=\"#H366578\" id=\"outline-link-H366578\">Imaging</a></li></ul></li><li><a href=\"#H605085221\" id=\"outline-link-H605085221\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H605085626\" id=\"outline-link-H605085626\">COMPLICATIONS</a></li><li><a href=\"#H3595492839\" id=\"outline-link-H3595492839\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H366717\" id=\"outline-link-H366717\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H675002085\" id=\"outline-link-H675002085\">ACKNOWLEDGMENTS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/5575|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=OBGYN/77990\" class=\"graphic graphic_picture\">- Hidradenitis suppurativa</a></li><li><a href=\"image.htm?imageKey=OBGYN/65884\" class=\"graphic graphic_picture\">- Moderate hidradenitis suppurativa</a></li><li><a href=\"image.htm?imageKey=OBGYN/65188\" class=\"graphic graphic_picture\">- Severe hidradenitis suppurativa</a></li><li><a href=\"image.htm?imageKey=DERM/69605\" class=\"graphic graphic_picture\">- HS abscess</a></li><li><a href=\"image.htm?imageKey=DERM/52570\" class=\"graphic graphic_picture\">- HS sinus1</a></li><li><a href=\"image.htm?imageKey=DERM/90463\" class=\"graphic graphic_picture\">- Hidradenitis suppurativa Hurley stage I</a></li><li><a href=\"image.htm?imageKey=DERM/90464\" class=\"graphic graphic_picture\">- Hidradenitis suppurativa Hurley stage II</a></li><li><a href=\"image.htm?imageKey=DERM/90465\" class=\"graphic graphic_picture\">- Hidradenitis suppurativa Hurley stage III</a></li><li><a href=\"image.htm?imageKey=DERM/90466\" class=\"graphic graphic_picture\">- Hidradenitis suppurativa pathology</a></li><li><a href=\"image.htm?imageKey=OBGYN/81233\" class=\"graphic graphic_picture\">- HS Crohns1</a></li><li><a href=\"image.htm?imageKey=OBGYN/58354\" class=\"graphic graphic_picture\">- HS Crohns2</a></li><li><a href=\"image.htm?imageKey=OBGYN/71166\" class=\"graphic graphic_picture\">- HS granuloma inguinale</a></li></ul></li><li><div id=\"DERM/5575|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/75490\" class=\"graphic graphic_table\">- Hidradenitis suppurativa - associated disorders</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cellulitis and skin abscess: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis and prognosis of Crohn disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-diagnosis-of-hair-loss\" class=\"medical medical_review\">Evaluation and diagnosis of hair loss</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hidradenitis-suppurativa-treatment\" class=\"medical medical_review\">Hidradenitis suppurativa: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perianal-complications-of-crohn-disease\" class=\"medical medical_review\">Perianal complications of Crohn disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pilonidal-disease\" class=\"medical medical_review\">Pilonidal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pyogenic-granuloma-lobular-capillary-hemangioma\" class=\"medical medical_review\">Pyogenic granuloma (Lobular capillary hemangioma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hidradenitis-suppurativa\" class=\"medical medical_society_guidelines\">Society guideline links: Hidradenitis suppurativa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">The metabolic syndrome (insulin resistance syndrome or syndrome X)</a></li></ul></div></div>","javascript":null}